{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T23:33:57Z","timestamp":1782516837917,"version":"3.54.5"},"reference-count":79,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.eprac.2023.06.012","type":"journal-article","created":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T21:24:25Z","timestamp":1688419465000},"page":"912-918","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Identification of High-Risk Patients With Nonalcoholic Fatty Liver Disease in Endocrinology Clinics"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9313-577X","authenticated-orcid":false,"given":"Zobair M.","family":"Younossi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Isaacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Cusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.eprac.2023.06.012_bib3","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/gutjnl-2017-313884","article-title":"Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases","volume":"66","author":"Adams","year":"2017","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.eprac.2023.06.012_bib4","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jhep.2017.09.003","article-title":"Genetics and epigenetics of NAFLD and NASH: clinical impact","volume":"68","author":"Eslam","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.eprac.2023.06.012_bib5","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s12902-022-01046-y","article-title":"Association between type 2 diabetes status and prevalence of liver steatosis and fibrosis among adults aged \u2265 40 years","volume":"22","author":"Chen","year":"2022","journal-title":"BMC Endocr Disord"},{"issue":"5","key":"10.1016\/j.eprac.2023.06.012_bib6","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/hep.31173","article-title":"Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of NAFLD","volume":"72","author":"Paik","year":"2020","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.eprac.2023.06.012_bib7","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1002\/hep4.1915","article-title":"Nonalcoholic steatohepatitis is the most common indication for liver transplantation among the elderly: data from the United States scientific registry of transplant recipients","volume":"6","author":"Stepanova","year":"2022","journal-title":"Hepatol Commun"},{"issue":"12","key":"10.1016\/j.eprac.2023.06.012_bib8","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1016\/j.cgh.2021.10.018","article-title":"The impact of NASH to liver transplantations with hepatocellular carcinoma in the United States","volume":"20","author":"Younossi","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.eprac.2023.06.012_bib9","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.cgh.2020.05.064","article-title":"Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States","volume":"19","author":"Younossi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.eprac.2023.06.012_bib10","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.eprac.2023.06.012_bib11","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.eprac.2023.06.012_bib12","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1002\/hep.32228","article-title":"Global burden of NAFLD and chronic liver disease among adolescents and young\u00a0adults","volume":"75","author":"Paik","year":"2022","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.eprac.2023.06.012_bib13","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/hep4.1707","article-title":"Dietary risks for liver mortality in NAFLD: global burden of disease data","volume":"6","author":"Paik","year":"2022","journal-title":"Hepatol Commun"},{"issue":"3","key":"10.1016\/j.eprac.2023.06.012_bib14","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41575-021-00565-8","article-title":"Natural history of NAFLD: knowns and unknowns","volume":"19","author":"Tsochatzis","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.eprac.2023.06.012_bib15","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.jhep.2022.07.004","article-title":"Clinical course of non-alcoholic fatty liver disease and the implications for clinical trial design","volume":"77","author":"Allen","year":"2022","journal-title":"J\u00a0Hepatol"},{"issue":"9","key":"10.1016\/j.eprac.2023.06.012_bib16","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.30426","article-title":"Analysis of a simulation model to estimate long-term outcomes in patients with nonalcoholic fatty liver disease","volume":"5","author":"Chhatwal","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.eprac.2023.06.012_bib17","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"Singh","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.eprac.2023.06.012_bib18","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/hep.21327","article-title":"Long-term follow-up of patients with NAFLD and elevated liver enzymes","volume":"44","author":"Ekstedt","year":"2006","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.eprac.2023.06.012_bib19","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2036.2011.04724.x","article-title":"Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults","volume":"34","author":"Vernon","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.eprac.2023.06.012_bib20","article-title":"Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma","volume":"3","author":"Younossi","year":"2021","journal-title":"JHEP Rep"},{"issue":"2","key":"10.1016\/j.eprac.2023.06.012_bib21","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1136\/gut.2003.024935","article-title":"Cytokines and the pathogenesis of non-alcoholic steatohepatitis","volume":"54","author":"Diehl","year":"2005","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.eprac.2023.06.012_bib22","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/ijc.23995","article-title":"Nonalcoholic steatohepatitis induced by a high-fat diet promotes diethylnitrosamine-initiated early hepatocarcinogenesis in rats","volume":"124","author":"Wang","year":"2009","journal-title":"Int J Cancer"},{"issue":"22","key":"10.1016\/j.eprac.2023.06.012_bib23","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.4254\/wjh.v7.i22.2384","article-title":"Pathogenesis of hepatocarcinogenesis in non-cirrhotic nonalcoholic fatty liver disease: potential mechanistic pathways","volume":"7","author":"Perumpail","year":"2015","journal-title":"World J Hepatol"},{"issue":"5","key":"10.1016\/j.eprac.2023.06.012_bib24","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.eprac.2023.06.012_bib25","doi-asserted-by":"crossref","first-page":"9","DOI":"10.14218\/JCTH.2015.00001","article-title":"Diabetes mellitus predicts occurrence of cirrhosis and hepatocellular cancer in alcoholic liver and non-alcoholic fatty liver diseases","volume":"3","author":"Raff","year":"2015","journal-title":"J\u00a0Clin Transl Hepatol"},{"issue":"7","key":"10.1016\/j.eprac.2023.06.012_bib26","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/ijc.26165","article-title":"Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies","volume":"130","author":"Wang","year":"2012","journal-title":"Int J Cancer"},{"issue":"10","key":"10.1016\/j.eprac.2023.06.012_bib27","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1111\/liv.12903","article-title":"Hyperinsulinaemia and insulin signalling in the pathogenesis and the clinical course of hepatocellular carcinoma","volume":"35","author":"Chettouh","year":"2015","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.eprac.2023.06.012_bib28","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/hep4.1625","article-title":"The natural history of NAFLD, a community-based study at a large health care delivery system in the United States","volume":"5","author":"Nyberg","year":"2021","journal-title":"Hepatol Commun"},{"issue":"2","key":"10.1016\/j.eprac.2023.06.012_bib29","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2337\/dc20-1778","article-title":"High prevalence of advanced liver fibrosis assessed by transient elastography among U.S. adults with type 2 diabetes","volume":"44","author":"Ciardullo","year":"2021","journal-title":"Diabetes Care"},{"issue":"17","key":"10.1016\/j.eprac.2023.06.012_bib30","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in adults with nonalcoholic fatty liver disease","volume":"385","author":"Sanyal","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eprac.2023.06.012_bib31","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13098-020-00570-y","article-title":"NAFLD as a continuum: from obesity to metabolic syndrome and diabetes","volume":"12","author":"Godoy-Matos","year":"2020","journal-title":"Diabetol Metab Syndr"},{"issue":"11","key":"10.1016\/j.eprac.2023.06.012_bib32","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1111\/apt.15679","article-title":"Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data","volume":"51","author":"Loomba","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.eprac.2023.06.012_bib33","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1111\/apt.16016","article-title":"Patterns and predictors of mortality and disease progression among patients with non-alcoholic fatty liver disease","volume":"52","author":"Canbay","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.eprac.2023.06.012_bib34","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.eprac.2023.06.012_bib35","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.eprac.2023.06.012_bib36","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3748\/wjg.v20.i2.475","article-title":"Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"20","author":"Sumida","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"6","key":"10.1016\/j.eprac.2023.06.012_bib37","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.jhep.2022.03.026","article-title":"Impact of non-invasive biomarkers on hepatology practice: past, present and future","volume":"76","author":"Anstee","year":"2022","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.eprac.2023.06.012_bib38","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jhep.2019.03.033","article-title":"Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease","volume":"71","author":"Srivastava","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.eprac.2023.06.012_bib39","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1053\/j.gastro.2022.06.023","article-title":"AGA clinical practice update: diagnosis and management of nonalcoholic fatty liver disease in lean individuals: expert review","volume":"163","author":"Long","year":"2022","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.eprac.2023.06.012_bib40","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1053\/j.gastro.2021.07.049","article-title":"Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease","volume":"161","author":"Kanwal","year":"2021","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.eprac.2023.06.012_bib41","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr Pract"},{"issue":"3","key":"10.1016\/j.eprac.2023.06.012_bib42","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/apt.15830","article-title":"Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices","volume":"52","author":"Younossi","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.eprac.2023.06.012_bib43","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.3390\/cells9041005","article-title":"Noninvasive diagnosis of NAFLD and NASH","volume":"9","author":"Piazzolla","year":"2020","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.eprac.2023.06.012_bib44","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.eprac.2023.06.012_bib45","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1053\/gast.2002.35354","article-title":"The utility of radiological imaging in nonalcoholic fatty liver disease","volume":"123","author":"Saadeh","year":"2002","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.eprac.2023.06.012_bib46","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1056\/NEJMoa0901249","article-title":"Exposure to low-dose ionizing radiation from medical imaging procedures","volume":"361","author":"Fazel","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.eprac.2023.06.012_bib47","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1002\/hep.26455","article-title":"Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials","volume":"58","author":"Noureddin","year":"2013","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.eprac.2023.06.012_bib48","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.jhep.2016.12.022","article-title":"Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis","volume":"66","author":"Karlas","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.eprac.2023.06.012_bib49","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jhep.2021.04.044","article-title":"Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: a systematic review and meta-analysis","volume":"75","author":"Selvaraj","year":"2021","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.eprac.2023.06.012_bib50","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jhep.2016.06.005","article-title":"MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: clinical trials to clinical practice","volume":"65","author":"Dulai","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.eprac.2023.06.012_bib51","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1002\/hep.29639","article-title":"Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis","volume":"67","author":"Caussy","year":"2018","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.eprac.2023.06.012_bib52","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1053\/j.gastro.2019.01.042","article-title":"Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease","volume":"156","author":"Eddowes","year":"2019","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.eprac.2023.06.012_bib53","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1136\/gutjnl-2021-324243","article-title":"Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis","volume":"71","author":"M\u00f3zes","year":"2022","journal-title":"Gut"},{"issue":"10","key":"10.1016\/j.eprac.2023.06.012_bib54","first-page":"661","article-title":"Noninvasive diagnosis of NASH and liver fibrosis within the spectrum of NAFLD","volume":"8","author":"Alkhouri","year":"2012","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"4","key":"10.1016\/j.eprac.2023.06.012_bib55","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1080\/17474124.2019.1579641","article-title":"Non-invasive assessment of liver fibrosis and prognosis: an update on serum and elastography markers","volume":"13","author":"Agbim","year":"2019","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.eprac.2023.06.012_bib56","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2337\/dc20-1997","article-title":"Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting: the need for systematic screening","volume":"44","author":"Lomonaco","year":"2021","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.eprac.2023.06.012_bib57","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1002\/oby.23263","article-title":"Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease","volume":"29","author":"Barb","year":"2021","journal-title":"Obesity (Silver Spring)"},{"issue":"1","key":"10.1016\/j.eprac.2023.06.012_bib59","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.21669","article-title":"FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest","volume":"46","author":"Vallet-Pichard","year":"2007","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.eprac.2023.06.012_bib60","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jhep.2017.11.013","article-title":"Non-invasive assessment of non-alcoholic fatty liver disease: clinical prediction rules and blood-based biomarkers","volume":"68","author":"Vilar-Gomez","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.eprac.2023.06.012_bib61","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD","volume":"45","author":"Angulo","year":"2007","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.eprac.2023.06.012_bib62","doi-asserted-by":"crossref","first-page":"e2008","DOI":"10.1210\/clinem\/dgab933","article-title":"Obesity modifies the performance of fibrosis biomarkers in nonalcoholic fatty liver disease","volume":"107","author":"Qadri","year":"2022","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.eprac.2023.06.012_bib63","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/ajg.2016.453","article-title":"Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis","volume":"112","author":"McPherson","year":"2017","journal-title":"Am J Gastroenterol"},{"issue":"13","key":"10.1016\/j.eprac.2023.06.012_bib64","first-page":"2910","article-title":"Systematic review with meta-analyses: diagnostic accuracy of FibroMeter tests in patients with non-alcoholic fatty liver disease","volume":"10","author":"Van Dijk","year":"2021","journal-title":"J\u00a0Clin Med"},{"issue":"11","key":"10.1016\/j.eprac.2023.06.012_bib65","first-page":"2415","article-title":"FibroTest for evaluating fibrosis in non-alcoholic fatty liver disease patients: a systematic review and meta-analysis","volume":"10","author":"Vali","year":"2021","journal-title":"J\u00a0Clin Med"},{"issue":"4","key":"10.1016\/j.eprac.2023.06.012_bib66","doi-asserted-by":"crossref","first-page":"e397","DOI":"10.5301\/ijbm.5000292","article-title":"Enhanced liver fibrosis test as a reliable tool for assessing fibrosis in nonalcoholic fatty liver disease in a clinical setting","volume":"32","author":"Miele","year":"2017","journal-title":"Int J Biol Markers"},{"key":"10.1016\/j.eprac.2023.06.012_bib67","doi-asserted-by":"crossref","unstructured":"Vali Y, Lee J, Boursier J, et\u00a0al(\u2020). Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: a systematic review and meta-analysis. J Hepatol. 2020;73(2):252-262. https:\/\/doi.org\/10.1016\/j.jhep.2020.03.036.","DOI":"10.1016\/j.jhep.2020.03.036"},{"issue":"4","key":"10.1016\/j.eprac.2023.06.012_bib68","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/hep4.1852","article-title":"Predicting liver-related outcomes in people with nonalcoholic fatty liver disease: the prognostic value of noninvasive fibrosis tests","volume":"6","author":"Johnson","year":"2022","journal-title":"Hepatol Commun"},{"issue":"9","key":"10.1016\/j.eprac.2023.06.012_bib69","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1136\/gut.2009.203166","article-title":"Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease","volume":"59","author":"Parkes","year":"2010","journal-title":"Gut"},{"issue":"9","key":"10.1016\/j.eprac.2023.06.012_bib70","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1373\/clinchem.2018.289108","article-title":"Enhanced liver fibrosis score as a predictor of hepatocellular carcinoma","volume":"64","author":"Loo","year":"2018","journal-title":"Clin Chem"},{"issue":"5","key":"10.1016\/j.eprac.2023.06.012_bib71","first-page":"815","article-title":"Derivation and performance of standardized enhanced liver fibrosis (ELF) test thresholds for the detection and prognosis of liver fibrosis","volume":"3","author":"Day","year":"2019","journal-title":"J\u00a0Appl Lab Med"},{"issue":"3","key":"10.1016\/j.eprac.2023.06.012_bib72","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/liv.12896","article-title":"The enhanced liver fibrosis score is associated with clinical outcomes and disease progression in patients with chronic liver disease","volume":"36","author":"Irvine","year":"2016","journal-title":"Liver Int"},{"issue":"6","key":"10.1016\/j.eprac.2023.06.012_bib73","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.cgh.2020.06.070","article-title":"Enhanced liver fibrosis score can be used to predict liver-related events in patients with nonalcoholic steatohepatitis and compensated cirrhosis","volume":"19","author":"Are","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.eprac.2023.06.012_bib74","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.23923","article-title":"Performance of the enhanced liver fibrosis test to estimate advanced fibrosis among patients with nonalcoholic fatty liver disease","volume":"4","author":"Younossi","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"9","key":"10.1016\/j.eprac.2023.06.012_bib76","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1111\/liv.14593","article-title":"MR elastography-based liver fibrosis correlates with liver events in nonalcoholic fatty liver patients: a multicenter study","volume":"40","author":"Han","year":"2020","journal-title":"Liver Int"},{"issue":"4","key":"10.1016\/j.eprac.2023.06.012_bib77","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.cgh.2020.12.016","article-title":"Direct comparison of US and MR elastography for staging liver fibrosis in patients with nonalcoholic fatty liver disease","volume":"20","author":"Imajo","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.eprac.2023.06.012_bib78","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/hep.32594","article-title":"Change in serial liver stiffness measurement by magnetic resonance elastography and outcomes in NAFLD","volume":"77","author":"Gidener","year":"2023","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.eprac.2023.06.012_bib79","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S2468-1253(19)30383-8","article-title":"FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study","volume":"5","author":"Newsome","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.eprac.2023.06.012_bib80","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.jhep.2021.11.012","article-title":"MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis","volume":"76","author":"Noureddin","year":"2022","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.eprac.2023.06.012_bib81","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1053\/j.gastro.2022.06.073","article-title":"Liver stiffness on magnetic resonance elastography and the MEFIB index and liver-related outcomes in nonalcoholic fatty liver disease: a systematic review and meta-analysis of individual participants","volume":"163","author":"Ajmera","year":"2022","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.eprac.2023.06.012_bib82","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1053\/j.gastro.2022.06.073","article-title":"Liver stiffness on magnetic resonance elastography and the MEFIB index and liver-related outcomes in nonalcoholic fatty liver disease: a systematic review and meta-analysis of individual participants","volume":"163","author":"Ajmera","year":"2022","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.eprac.2023.06.012_bib83","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/apt.17346","article-title":"A\u00a0practical use of noninvasive tests in clinical practice to identify high-risk patients with nonalcoholic steatohepatitis","volume":"57","author":"Younossi","year":"2023","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X2300469X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X2300469X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:15:23Z","timestamp":1761516923000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X2300469X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":79,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S1530891X2300469X"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2023.06.012","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of High-Risk Patients With Nonalcoholic Fatty Liver Disease in Endocrinology Clinics","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2023.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 AACE. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}